Treatment Information


Rectal Cancer treatment details. Chemotherapy, Radiation.

Centre Antoine-Lacassagne, Nice, France.

Survival: monthsCountry:France
Toxiciy Grade:4City/State/Province:Nice
Treatments:Chemotherapy, RadiationHospital:Centre Antoine-Lacassagne
Date:Dec 2005


Patients: This Phase I study involved 43 patients with locally advanced or metastatic rectal cancer. Thirty-four patients were men, nine were women, and the median age was 59 years.

Treatment: The treatment consisted of radiotherapy and two chemotherapeutic agents: fluorouracil and oxaliplatin.

Toxicity: Grade 3-4 toxicities included anemia, thrombocytopenia, diarrhea, urinary tract toxicity, and asthenia.

Results: The median overall survival was not reported. Two complete responses and 19 partial responses were observed.

Support: Sanofi-Synthelabo financially supported this study. Sanofi-Synthelabo manufactures and/or markets oxaliplatin.

Correspondence: Eric Francois, MD